0001787306-24-000036.txt : 20240306
0001787306-24-000036.hdr.sgml : 20240306
20240306170824
ACCESSION NUMBER: 0001787306-24-000036
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240304
FILED AS OF DATE: 20240306
DATE AS OF CHANGE: 20240306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Moore Matthew Richard
CENTRAL INDEX KEY: 0001840191
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39186
FILM NUMBER: 24726936
MAIL ADDRESS:
STREET 1: C/O ARCUTIS BIOTHERAPEUTICS, INC.
STREET 2: 3027 TOWNSGATE ROAD, SUITE 300
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcutis Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001787306
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 812974255
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3027 TOWNSGATE ROAD
STREET 2: SUITE 300
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
BUSINESS PHONE: 805-418-5006
MAIL ADDRESS:
STREET 1: 3027 TOWNSGATE ROAD
STREET 2: SUITE 300
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91361
FORMER COMPANY:
FORMER CONFORMED NAME: Arcutis, Inc.
DATE OF NAME CHANGE: 20190905
4
1
wk-form4_1709762890.xml
FORM 4
X0508
4
2024-03-04
0
0001787306
Arcutis Biotherapeutics, Inc.
ARQT
0001840191
Moore Matthew Richard
C/O ARCUTIS BIOTHERAPEUTICS, INC.
3027 TOWNSGATE ROAD, SUITE 300
WESTLAKE VILLAGE
CA
91361
0
1
0
0
SVP and Chief Business Officer
1
Common Stock
2024-03-04
4
S
0
3468
11.1212
D
146020
D
The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units.
The transaction was executed in multiple trades in prices ranging from $11.000 to $11.3200, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Reporting Person's title: Senior Vice President and Chief Business Officer
/s/ John W. Smither, Attorney-in-Fact for Matthew Richard Moore
2024-03-06